Titania nanoparticles damage enveloped viruses by directly binding with membrane phospholipids – a previously unknown mode of antiviral action ...
Protein complex in bacterial cell membrane acts like a rotary motor to recruit DNA-degrading enzymes to defend against phage ...
Uganda has confirmed an outbreak of Sudan virus disease, with the first case linked to a 32-year-old nurse in Kampala.
Influenza A virus particles strategically adapt their shape -- to become either spheres or larger filaments -- to favor their ability to infect cells depending on environmental conditions, according ...
4d
News Medical on MSNInfluenza A virus changes shape to evade immune responsesInfluenza A virus particles strategically adapt their shape-to become either spheres or larger filaments-to favor their ability to infect cells depending on environmental conditions, according to a ...
The influenza A virus genome consists of eight segments of single-stranded, negative-sense viral RNA, which encode multiple ...
4d
AZoLifeSciences on MSNNew Study Explains Why Flu Virus Forms FilamentsInfluenza A virus particles strategically modify their shape becoming either spheres or larger filaments to enhance their ...
3d
Hosted on MSNWhat Is Sudan Virus and How Similar Is It to Ebola? [analysis]The Ugandan government and the World Health Organization recently confirmed an outbreak of Sudan virus disease. The index (first-known) case of this outbreak is thought to be a 32-year-old male nurse ...
One person was injured in an automotive mechanic shop fire that happened Saturday in Cherokee County near Canton.
Human uptake of microplastic particles (MPs) is causing increasing health concerns, and there is mounting pressure to evaluate the associated risks. While MPs can be ingested, breathed in, or drank in ...
This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...
U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for priority review with a PDUFA date of July 22, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results